Know Cancer

forgot password

A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens

Phase 2
18 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens

Inclusion Criteria

Inclusion Criteria

- Stage IIIB or IV non-small cell lung cancer.

- Recurrent tumor following treatment with paclitaxel or docetaxel.

- Able to tolerate normal activities of daily living.

- Adequate bone marrow, kidney and liver function.

Exclusion Criteria

- Pregnant or breast feeding.

- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.

- CNS metastasis.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate in subjects with NSCLC

Outcome Time Frame:

1 year

Principal Investigator

Helen Eliopoulos, MD

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

September 2003

Completion Date:

January 2006

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Washington University School of MedicineSaint Louis, Missouri  63110
University of Wisconsin Comprehensive Cancer CenterMadison, Wisconsin  53792
Albany Regional Cancer CenterAlbany, New York  12208
Cancer Centers of the CarolinasGreenville, South Carolina  29605
Cancer Care NorthwestSpokane, Washington  99202
Cancer Care AssociatesTulsa, Oklahoma  74136
Northwest Cancer SpecialistsVancouver, Washington  98664
West Cancer ClinicMemphis, Tennessee  38120
University of Chicago Medical CenterChicago, Illinois  60637
University of Maryland Greenbaum Cancer CenterBaltimore, Maryland  21201
Oncology Hematology Group of South FloridaMiami, Florida  33176
Texas OncologyDallas, Texas  
Florida Cancer InstituteNew Port Richey, Florida  34652
Oncology & Hematology Associates of Kansas City, PAKansas City, Missouri  64111
Raleigh Hematology OncologyCary, North Carolina  
Dayton Oncology and HematologyKettering, Ohio